Because PRMT5 is required to maintain proper splicing of full-length EP400 in a MYC-driven lymphomagenesis mouse model and has also been reported to promote full-length KAT5 splicing in hematopoietic cells (Koh et al, 2015; Hamard et al, 2018), we tested the effect of PRMT5 inhibition on their splicing in MCC cells using Western blot analysis. Here, MYC is linked to Merkel cell skin cancer.